Live from the NIH registry
Studies recruiting near Santa Rosa right now
Top 25 of 147 recruiting studies, sorted by proximity — each links to its official registry page
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Malignancy
N/A
Observational 240 participants sought
Saint Helena Hospital — St. Helena, California (13.4 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 3
Interventional 1,145 participants sought
Research Site — Santa Rosa, California (0.6 mi)
· Sponsor: AstraZeneca
Patient Specific Talus Spacer Post Approval Study
Avascular Necrosis of the Talus
N/A
Observational 50 participants sought
Redwood Orthopaedics — Santa Rosa, California (0.6 mi)
· Sponsor: Paragon 28
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
Primary Open Angle Glaucoma
Phase 3
Interventional 130 participants sought
North Bay Eye Associates /ID# 277071 — Petaluma, California (15.2 mi)
· Sponsor: AbbVie
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
Phase 3
Interventional 356 participants sought
Sutter Pacific Medical Foundation — Santa Rosa, California (0.6 mi)
· Sponsor: NRG Oncology
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
Saint Helena Hospital — St. Helena, California (13.4 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma
Phase 2
Interventional 146 participants sought
Kaiser Permanente-Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: NRG Oncology
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Providence Medical Foundation - Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Phase 3
Interventional 1,530 participants sought
Providence Medical Foundation ( Site 9543) — Santa Rosa, California (0.6 mi)
· Sponsor: Merck Sharp & Dohme LLC
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 2,000 participants sought
Kaiser Permanente-Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Phase 3
Interventional 1,209 participants sought
Kaiser Permanente-Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: NRG Oncology
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Phase 3
Interventional 5,056 participants sought
NorthBay Clinical Research LLC — Santa Rosa, California (0.6 mi)
· Sponsor: Amgen
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Phase 1, Phase 2
Interventional 340 participants sought
Providence Medical Foundation — Santa Rosa, California (0.6 mi)
· Sponsor: Inhibrx Biosciences, Inc
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Phase 3
Interventional 228 participants sought
Kaiser Permanente-Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Phase 3
Interventional 1,057 participants sought
Providence Medical Foundation - Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: SWOG Cancer Research Network
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Stage I Breast Cancer
Phase 3
Interventional 1,670 participants sought
Kaiser Permanente-Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: NRG Oncology
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Cardiotoxicity, HER2/Neu Positive
Phase 3
Interventional 491 participants sought
Kaiser Permanente-Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: SWOG Cancer Research Network
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
Phase 1
Interventional 174 participants sought
Providence Medical Group Oncology Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: Astellas Pharma Global Development, Inc.
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Small Cell Lung Cancer Extensive Stage
Phase 1, Phase 2
Interventional 170 participants sought
Providence Medical Foundation ( Site 0124) — Santa Rosa, California (0.6 mi)
· Sponsor: Merck Sharp & Dohme LLC
SELUTION4BTK Trial
Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
N/A
Interventional 376 participants sought
St. Helena Hospital — St. Helena, California (13.4 mi)
· Sponsor: M.A. Med Alliance S.A.
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
Colorectal Cancer, CRC (Colorectal Cancer)
Phase 2
Interventional 136 participants sought
NGM Clinical Study Site — Santa Rosa, California (0.6 mi)
· Sponsor: NGM Biopharmaceuticals, Inc
Tracking Results of Ablations to Combat AF Registry Generation 2
Atrial Fibrillation
N/A
Observational 10,000 participants sought
Adventist Heart Institute (St. Helena Hospital) — St. Helena, California (13.4 mi)
· Sponsor: AtriCure, Inc.
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 3
Interventional 880 participants sought
Kaiser Permanente-Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: NRG Oncology
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
N/A
Observational 2,000 participants sought
Providence Medical Foundation - Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Phase 2
Interventional 156 participants sought
Kaiser Permanente-Santa Rosa — Santa Rosa, California (0.6 mi)
· Sponsor: National Cancer Institute (NCI)